Inari Medical, Inc.
NARI · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $494 | $383 | $277 | $140 |
| % Growth | 28.7% | 38.4% | 98.3% | – |
| Cost of Goods Sold | $59 | $45 | $25 | $13 |
| Gross Profit | $435 | $339 | $252 | $127 |
| % Margin | 88% | 88.4% | 91.1% | 90.6% |
| R&D Expenses | $88 | $74 | $51 | $18 |
| G&A Expenses | $349 | $292 | $190 | $89 |
| SG&A Expenses | $351 | $293 | $190 | $90 |
| Sales & Mktg Exp. | $1 | $1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$0 | -$1 |
| Operating Expenses | $449 | $367 | $241 | $108 |
| Operating Income | -$14 | -$28 | $7 | $18 |
| % Margin | -2.8% | -7.3% | 2.4% | 13.2% |
| Other Income/Exp. Net | $18 | $2 | -$0 | -$5 |
| Pre-Tax Income | $4 | -$26 | $11 | $14 |
| Tax Expense | $6 | $3 | $1 | $0 |
| Net Income | -$2 | -$29 | $10 | $14 |
| % Margin | -0.3% | -7.6% | 3.6% | 9.9% |
| EPS | -0.029 | -0.55 | 0.2 | 0.43 |
| % Growth | 94.8% | -375% | -53.5% | – |
| EPS Diluted | -0.029 | -0.55 | 0.18 | 0.27 |
| Weighted Avg Shares Out | 57 | 53 | 50 | 32 |
| Weighted Avg Shares Out Dil | 57 | 53 | 56 | 52 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $2 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $1 |
| Depreciation & Amortization | $11 | $8 | $5 | $1 |
| EBITDA | $15 | -$18 | $16 | $16 |
| % Margin | 3.1% | -4.8% | 5.6% | 11.7% |